Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595866 | 0.89 | ENPP2 (0.50) | PRKCAPRKCEPRKCQPRKCDLPAR1 | |
| SCHEMBL31615051 | 0.88 | PRKCA (0.58) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9464928 | 0.84 | MGLL (0.46) | CNR1DGKA | |
| SCHEMBL27160928 | 0.84 | MGLL (0.46) | CNR1DGKA | |
| SCHEMBL9464941 | 0.84 | MGLL (0.46) | CNR1DGKA | |
| SCHEMBL30028349 | 0.84 | MGLL (0.46) | CNR1DGKA | |
| SCHEMBL5595684 | 0.82 | LPAR1 (0.38) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL10492119 | 0.82 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL7557200 | 0.82 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL7557194 | 0.82 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | PRKCA 736/4885PRKCE 841/4885PRKCQ 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.